Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Publication year range
1.
Chin J Integr Med ; 28(12): 1063-1071, 2022 Dec.
Article in English | MEDLINE | ID: mdl-36251140

ABSTRACT

OBJECTIVE: To examine whether the combination of Naoxintong Capsule with standard care could further reduce the recurrence of ischemic stroke without increasing the risk of severe bleeding. METHODS: A total of 23 Chinese medical centers participated in this trial. Adult patients with a history of ischemic stroke were randomly assigned in a 1:1 ratio using a block design to receive either Naoxintong Capsule (1.2 g orally, twice a day) or placebo in addition to standard care. The primary endpoint was recurrence of ischemic stroke within 2 years. Secondary outcomes included myocardial infarction, death due to recurrent ischemic stroke, and all-cause mortality. The safety of drugs was monitored. Results were analyzed using the intention-to-treat principle. RESULTS: A total of 2,200 patients were enrolled from March 2015 to March 2016, of whom 143 and 158 in the Naoxintong and placebo groups were lost to follow-up, respectively. Compared with the placebo group, the recurrence rate of ischemic stroke within 2 years was significantly lower in the Naoxintong group [6.5% vs. 9.5%, hazard ratio (HR): 0.665, 95% confidence interval (CI): 0.492-0.899, P=0.008]. The two groups showed no significant differences in the secondary outcomes and safety, including rates of severe hemorrhage, cerebral hemorrhage and subarachnoid hemorrhage (P>0.05). CONCLUSION: The combination of Naoxintong Capsule with standard care reduced the 2-year stroke recurrence rate in patients with ischemic stroke without increasing the risk of severe hemorrhage in high-risk patients. (Trial registration No. NCT02334969).


Subject(s)
Ischemic Stroke , Stroke , Adult , Humans , Secondary Prevention/methods , Stroke/drug therapy , Stroke/prevention & control , Cerebral Hemorrhage/drug therapy , Cerebral Hemorrhage/complications , Double-Blind Method , Platelet Aggregation Inhibitors
2.
Ying Yong Sheng Tai Xue Bao ; 33(12): 3427-3432, 2022 Dec.
Article in Chinese | MEDLINE | ID: mdl-36601850

ABSTRACT

To investigate the responses of morphological and physiological characteristics in tadpoles of Pelophylax nigromaculatus to various water levels, a total of 480 tadpoles with similar sizes were treated with rapid, moderate and slow desiccation. Both the metamorphosis duration and average metamorphosis survival rate of specific developmental stages were counted. Their body and internal organ sizes, as well as the responsiveness to phytohemagglutinin (PHA-P) of froglets were measured after complete metamorphosis. The results showed that the metamorphosis duration of tadpoles in the control group was the longest. The average metamorphosis survival rate of different treatment groups ranged from 72.5% to 90.8%, which was the highest in the control group and the lowest in the rapid desiccation group. Body weight (BW) and body length (BL) of froglets in control and slow desiccation groups were significantly higher than those of moderate or rapid desiccation groups. Body width, ratio of BW to BL, carcass wet weight and the wet weight index of lung and fat body were the lowest in rapid desiccation group. There was no significant difference in the wet weight index of heart, spleen, kidneys and digestive organs, as well as the length index of different segments of whole digestive tract between groups. The maximal response value of froglets to PHA-P appeared at 3 h after injection in different treatments, which was significantly higher in moderate and slow desiccation groups than the control group. There was no significant difference between rapid desiccation group and any other groups. The tadpoles of P. nigromaculatus might accelerate the metamorphosis developmental process to cope with desiccation stress, accompanying with decreased atrophic body size and weakened cell-mediated immunity, which would harm tadpoles to successfully land.


Subject(s)
Water , Animals , Larva , Phytohemagglutinins/pharmacology , Phenotype , Body Size
3.
Pharmacogenomics ; 20(3): 167-177, 2019 02.
Article in English | MEDLINE | ID: mdl-30777785

ABSTRACT

AIM: To evaluate the accuracy and predictive performance of Bayesian dosing for warfarin in Chinese patients. MATERIALS & METHODS: Six multiple linear regression algorithms (Wei, Lou, Miao, Huang, Gage and IWPC) and a Bayesian method implemented in Warfarin Dose Calculator were compared with each other. RESULTS: Six multiple linear regression warfarin dosing algorithms had similar predictive ability, except Miao and Lou. The mean prediction error of Bayesian priori and posteriori method were 0.01 mg/day (95% CI: -0.18 to 0.19) and 0.17 mg/day (95% CI: -0.05 to 0.29), respectively, and Bayesian posteriori method demonstrated better performance in all dose ranges. CONCLUSION: The Bayesian method showed a good potential for warfarin maintenance dose prediction in Chinese patients requiring less than 6 mg/day.


Subject(s)
Anticoagulants/administration & dosage , Dose-Response Relationship, Drug , Pharmacogenetics , Warfarin/administration & dosage , Adult , Aged , Aged, 80 and over , Algorithms , Anticoagulants/adverse effects , Atrial Fibrillation/drug therapy , Bayes Theorem , Cytochrome P-450 CYP2C9/genetics , Ethnicity , Female , Genotype , Humans , International Normalized Ratio , Linear Models , Male , Middle Aged , Pulmonary Embolism/drug therapy , Venous Thrombosis/drug therapy , Warfarin/adverse effects
4.
World J Gastroenterol ; 19(40): 6794-804, 2013 Oct 28.
Article in English | MEDLINE | ID: mdl-24187454

ABSTRACT

Pulmonary abnormalities, dysfunction or hyper-reactivity occurs in association with inflammatory bowel disease (IBD) more frequently than previously recognized. Emerging evidence suggests that subtle inflammation exists in the airways among IBD patients even in the absence of any bronchopulmonary symptoms, and with normal pulmonary functions. The pulmonary impairment is more pronounced in IBD patients with active disease than in those in remission. A growing number of case reports show that the IBD patients develop rapidly progressive respiratory symptoms after colectomy, with failure to isolate bacterial pathogens on repeated sputum culture, and often request oral corticosteroid therapy. All the above evidence indicates that the inflammatory changes in both the intestine and lung during IBD. Clinical or subclinical pulmonary inflammation accompanies the main inflammation of the bowel. Although there are clinical and epidemiological reports of chronic inflammation of the pulmonary and intestinal mucosa in IBD, the detailed mechanisms of pulmonary-intestinal crosstalk remain unknown. The lung has no anatomical connection with the main inflammatory site of the bowel. Why does the inflammatory process shift from the gastrointestinal tract to the airways? The clinical and subclinical pulmonary abnormalities, dysfunction, or hyper-reactivity among IBD patients need further evaluation. Here, we give an overview of the concordance between chronic inflammatory reactions in the airways and the gastrointestinal tract. A better understanding of the possible mechanism of the crosstalk among the distant organs will be beneficial in identifying therapeutic strategies for mucosal inflammatory diseases such as IBD and allergy.


Subject(s)
Immunity, Mucosal , Inflammation Mediators/metabolism , Inflammatory Bowel Diseases/epidemiology , Intestines/immunology , Lung Diseases/epidemiology , Lung/immunology , Animals , Humans , Inflammatory Bowel Diseases/immunology , Inflammatory Bowel Diseases/metabolism , Inflammatory Bowel Diseases/microbiology , Inflammatory Bowel Diseases/therapy , Intestinal Mucosa/immunology , Intestinal Mucosa/metabolism , Intestines/microbiology , Lung/metabolism , Lung/microbiology , Lung Diseases/immunology , Lung Diseases/metabolism , Lung Diseases/microbiology , Lung Diseases/therapy , Prognosis , Respiratory Mucosa/immunology , Respiratory Mucosa/metabolism , Risk Factors , Signal Transduction
5.
Acta Pharmacol Sin ; 25(7): 861-8, 2004 Jul.
Article in English | MEDLINE | ID: mdl-15210058

ABSTRACT

AIM: To investigate the effect of tanshinone (Tan) on the neuropathological changes induced by amyloid beta-peptide1-40 (Abeta1-40) injection in hippocampus in rats. METHODS: Abeta1-40 10 microg was injected bilaterally into the dorsal blade of the dentate gyrus in the hippocampus. The level of acetylcholinesterase (AChE) in hippocampus was evaluated by histochemistry. The expressions of neuronal nitric oxide synthase (nNOS) and inducible form of NOS (iNOS) were detected by immunohistochemistry and Western blot. Abeta1-40-injected rats were treated ig with Tan, the major active ingredient from Salvia miltiorrhiza of Chinese herb extract. RESULTS: The level of AChE positive fibers of each subfield in Abeta1-40-injected hippocampus decreased significantly compared with those of control (P<0.01). The expression of nNOS was down-regulated whereas the iNOS was up-regulated. After treatment with Tan (50 mg/kg, ig), the changes mentioned above were significantly improved. Moreover, the correlation analysis revealed a significant negative correlation between the area percentage of AChE positive fibers and the number of iNOS positive neural cells in CA1, CA2 to CA3 (CA2-3), and dentate gyrus (DG) subfields (P<0.01). CONCLUSION: Tan can protect the neuropathological changes induced by Abeta1-40 injection in hippocampus.


Subject(s)
Amyloid beta-Peptides/toxicity , Hippocampus/pathology , Neuroprotective Agents/pharmacology , Peptide Fragments/toxicity , Phenanthrenes/pharmacology , Abietanes , Acetylcholinesterase/metabolism , Animals , Hippocampus/enzymology , Injections , Male , Neurons/enzymology , Neurons/pathology , Nitric Oxide Synthase/metabolism , Nitric Oxide Synthase Type I , Nitric Oxide Synthase Type II , Rats , Rats, Sprague-Dawley
SELECTION OF CITATIONS
SEARCH DETAIL
...